C-P5VFsmall-molecule oral therapy, synapse protection, toxic oligomer blockade
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Cognition Therapeutics states that it is focused on discovering and developing small-molecule therapeutics for Alzheimer's disease and other neurodegenerative diseases by targeting toxic proteins that drive cognitive decline. The company presents the belief that toxic proteins are central to these diseases, that no existing therapies adequately prevent their accumulation or block their damaging effects, and that its proprietary biological assays and medicinal chemistry can produce novel, high-quality drug candidates against these targets.
SourceCognition Therapeutics states that cognitive decline in Alzheimer's disease and other degenerative brain diseases is caused by toxic proteins, and that effective treatment should focus on discovering and developing novel small-molecule therapeutics that prevent toxic protein accumulation or block their destructive effects. The company presents this as an unmet medical need, emphasizing its belief that proprietary functional assays, biological expertise, and medicinal chemistry can produce high-quality drug candidates against these targets.
Source